Skip to main content

Table 1 Baseline variables of the included patients

From: Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden

Baseline variablesTotal
IPF-patients (N = 348)
 Incident / Prevalent (N, %)182 (52.3) / 166 (47.7)
 Gender (male /female) (N, %)250 (71.8) / 98 (28.1)
 Age (Median, range)72.0 (46–88)
 BMI (M ± SD)27.1 ± 4.2
Smoking habit (N = 348)
 Never smoker (N, %)103 (29.6)
 Ex-smoker (N, %)222 (63.8)
 Packyear (M ± SD) (Ex-smoker, n = 160)23.0 ± 15.0
 Smoker (N, %)12 (3.5)
 Missing info (N, %):11 (3.2)
Lung function
 FVC% (M ± SD) (N = 287)70.2 ± 15.6
 FEV1% (M ± SD) (N = 307)76.1 ± 16.6
 TLC% (M ± SD) (N = 193)63.9 ± 12.0
 DLCO% (M ± SD) (N = 221)46.2 ± 13.9
6-WMT (N = 198)
 6-WMD (M ± SD, m)422 ± 124
 B-SpO2% (M ± SD, %)95.8 ± 2.3
 L-SpO2% (M ± SD, %)86.1 ± 6.7
Comorbidity (N = 348)
 Arterial hypertension (N, %)115 (33.0)
 Gastroesophageal reflux (N, %)113 (32.5)
 Other cardiovasculara (N, %)86 (24.7)
 Coronary heart disease (N, %)67 (19.3)
 Diabetes (N, %)52 (14.9)
 Cancer (N, %)33 (9.5)
 Thyroid diseasesb (N, %)22 (6.3)
 Sleep apnea (N, %)22 (6.3)
 Asthma (N, %)15 (4.3)
 COPD (N, %)10 (2.9)
 Osteoporosis (N, %)6 (1.7)
 K-BILD (N = 292)53.7 ± 10.7
 Anti-fibrotic treatment (N, %)67 (19.3)
 Time from diagnosis to consent (median, Q1- Q3) (months)4 (Q1:0; Q3: 26)
  1. N number(s), M mean, SD standard deviation, BMI body mass index, FVC% forced vital capacity, % of expected, FEV1% forced expiratory volume in first second, % of expected, TLC% total lung capacity, % of expected, DLCO% % diffusing capacity for carbon monoxide, 6MWD 6 min walking distance, B-SpO2% Saturation level for oxygen, at rest, L-SpO2% Saturation level for oxygen, lowest during/after test, K-BILD King’s Brief Interstitial Lung Disease questionnaire
  2. aOther cardiovascular disease: Atrial fibrillation and Heart failure
  3. bThyroid diseases: hypo−/hyperthyroidism